NORWALK, Conn., Oct. 24, 2023 /PRNewswire/ — LifeSpan Vision Ventures today announced an investment in Matter Bio, a longevity holding company focused on preserving genome integrity. Central to the company’s philosophy is that as we age, our genome is constantly damaged by exogenous and endogenous sources. Errors are sometimes overlooked and incorporated into DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. Matter Bio has assembled a team of top scientists and executives to help counteract this loss of critical information in the genome. To achieve this, the company has adopted a hub and spoke model to advance multiple scientific advances, each of which intervenes in critical moments of information loss. To date, Matter Bio has three companies under its management, with other opportunities in incubation.
“Matter Bio continues to advance its commercial, clinical and research programs and the proceeds from the Lifespan Vision Venture investment will support the advancement of the company’s portfolio toward key scientific and commercial milestones,” said Chris Bradley, CEO of Matter Bio. .
Matter Bio expects to begin clinical trials for one of its programs in the next 12 months, as well as expand a program that is already generating revenue in the single-molecule mutation sequencing space.
Dr. Jordan B. Burton, Scientific Analyst at LifeSpan Vision Ventures, said, “Our investment in Matter Bio furthers our mission of supporting companies dedicated to longevity and curbing the key drivers of aging. The company’s business model brings academic expertise, efficiency and scale to pursue the mission of quantifying and reversing DNA damage to prevent diseases of aging and increase healthy lifespan. We are excited to work with such a talented team of pioneers in the genomics space and look forward to seeing how company can extend lifespan by counteracting critical loss of information in the genome.”
About Matter Bio
Matter Bio, co-founded with world-class scientists including George Church PhD. and Jan Vijg PhD., is a holding company that is driving multiple scientific advances, each of which points to a critical moment of information loss. Its main assets include precise sequencing of mutations, reversal of somatic mutations and elimination of pathological cells, including cancer.
For more information, visit https://matterbio.com/.
About LifeSpan Vision Ventures
LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in investments in the aging and longevity space. Our mission is to support and accelerate the development of innovative therapies that extend life expectancy, improve people’s quality of life as they age, and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where aging is met with vitality, resilience and infinite possibilities.
For more information about LifeSpan Vision Ventures, visit https://www.lifespanvisionventures.com/.
Contact: Harry RobbMobile: 44 7795042764harry.robb@lifespanvision.com
Photo – https://mma.prnewswire.com/media/2254743…
View original content: https://www.prnewswire.com/news-releases/lifespan-vision-ventures-invierte-en-matter-bio-301965857.html
